協創數據(300857.SZ):金通安益已減持89.47萬股 擬繼續減持不超4.14%股份
格隆匯2月18日丨協創數據(300857.SZ)公佈,截至本公吿日,股東金通安益減持計劃已期限屆滿,在該減持計劃期限內,金通安益通過集中競價交易方式累計減持公司股份89.47萬股,佔公司總股本的0.43%。
金通安益擬繼續減持公司股份不超過855.71萬股,不超過公司總股本4.14%,計劃在任意連續90日內通過集中競價減持不超過上市公司總股本1%,任意連續90日內通過大宗交易減持不超過上市公司總股本2%(若計劃減持期間公司有送股、資本公積轉增股本等變動事項,應對上述減持數量做相應調整)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.